The Economic Times

Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment

Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.